Description
Title: A New Approach to Breast Cancer Research Is Glycotherapy
Abstract: The Egyptians were the first to recognize breast cancer as a disease as far back as 1600 BC. In a chicken tumor virus, the first cancer-causing gene was discovered in 1970. The National Cancer Act, which authorized federal funding for cancer research, was ratified by the US in 1971. Breast cancer continues to rank among the most serious diseases that affect people, affecting as many as one in eight women over the course of their lifetime, despite multidisciplinary approaches that divert a lot of public and private resources. Five years of disease-free survival is no longer regarded as sufficient because of general difficulties and changes in the breast cancer landscape. Patients, families, and friends have expressed anxiety due to the lack of a cure, drug resistance, severe side effects, destruction of the patient’s quality of life, and the fact that therapy is frequently expensive and therefore out of reach for many. The fact that the approaches do not take cancer into account holistically is one of the reasons why cancer therapeutics have failed. All breast cancer cells and the capillary endothelial cells in their microenvironment express asparagine-linked (N-linked) glycoproteins with a variety of structures. We investigated Tunicamycin, a small biological molecule that inhibits the catalytic activity of N-acetylglusosaminyl 1-phosphate transferase, a particular step in the endoplasmic reticulum (ER) protein N-glycosylation pathway (GPT). The result was extremely thrilling. Tunicamycin has “zero” toxicity and inhibits angiogenesis quantitatively in vitro and in vivo, as well as multiple subtypes of breast tumor progression in pre-clinical mouse models. ER stress-induced unfolded protein response (upr) signaling is supported by mechanistic evidence as the reason for the apoptotic death of both cancer and microvascular endothelial cells. Furthermore, it obstructs Wnt signaling. Therefore, we draw the conclusion that tunicamycin can be anticipated to replace the current therapeutics and transition to a glycotherapy for the treatment of all subtypes of breast cancer.
Keywords: breast cancer; angiogenesis; glycotherapy; sparagine-linked glycoprotein; tunicamycin; N-acetylglucosaminyl 1-phosphate transferase; ER stress; unfolded protein response; upr
Paper Quality: SCOPUS / Web of Science Level Research Paper
Subject: Biomolecules
Writer Experience: 20+ Years
Plagiarism Report: Turnitin Plagiarism Report will be less than 10%
Restriction: Only one author may purchase a single paper. The paper will then indicate that it is out of stock.
What will I get after the purchase?
A turnitin plagiarism report of less than 10% in a pdf file and a full research paper in a word document.
In case you have any questions related to this research paper, please feel free to call/ WhatsApp on +919726999915
Reviews
There are no reviews yet.